What was the average price Progyny paid per share in Q2 2026?

Progyny repurchased nearly 1.2 million shares for $31.5 million, implying an average price of approximately $26.25 per share. The filing does not disclose the specific price range or execution window.

How much repurchase authorization remains?

Approximately $142.5 million remains under the May 2026 authorization of $200 million. The company has repurchased 2 million shares cumulatively to date under that program.

Why did Progyny start a new buyback program in May 2026 when it had a predecessor program?

The May 2026 program represented a new authorization, while the predecessor November 2025 program had concluded. The filing states that across both programs, the company has repurchased an aggregate 10.8 million shares, allowing Progyny to continue shareholder returns under the new authorization.

Does Progyny have sufficient cash to continue buybacks?

Yes. As of June 30, 2026, Progyny had $236.9 million in cash and marketable securities, no debt, and an undrawn $200 million revolving credit facility. The company's trailing twelve-month operating cash flow was $201.2 million, providing substantial financial flexibility.

What was the execution mechanism for the Q2 2026 buyback?

The filing does not specify whether the repurchases were executed under Rule 10b-18, a 10b5-1 plan, or another mechanism. Only the share count and total dollar amount are disclosed.

How do these buybacks affect Progyny's reported earnings per share?

Buybacks reduce share count, which mechanically supports earnings per share. In Q2 2026, diluted weighted-average shares outstanding were 82.1 million, down from 89.6 million in Q2 2025, reflecting both buyback activity and the company's organic focus on profitability expansion.

PGNY 8-K Filed 2026-08-06 Execution disclosure

Progyny repurchased 1.2M shares in Q2 2026 under $200M authorization

Women's health company returns capital to shareholders amid strong operational momentum and cash generation.

Shares repurchased1.2M

Avg price paid$26.25

Remaining$142M

MechanismNot specified

What the filing says

Progyny, Inc. (Nasdaq: PGNY) repurchased nearly 1.2 million shares of its common stock for a total cost of $31.5 million during the second quarter of 2026, executed under its May 2026 share repurchase program authorization of up to $200 million. To date, the company has repurchased a cumulative 2 million shares under this most recent program, leaving approximately $142.5 million remaining under the existing authorization.

The company's execution mechanism was not specified in the filing. The share repurchases were enabled by strong operational cash generation—the company reported net cash provided by operating activities of $50.4 million in Q2 2026, contributing to trailing twelve-month operating cash flow of $201.2 million. The company operates with no debt and cash and cash equivalents plus marketable securities of $236.9 million as of June 30, 2026.

In combination with a predecessor program that began in November 2025 and concluded earlier in 2026, Progyny has repurchased an aggregate 10.8 million shares across both its May 2026 and November 2025 share repurchase programs. The company's CFO noted that the strong second quarter results and "continued high conversion of Adjusted EBITDA to operating cash flow" provided flexibility to both invest in platform development and return capital to shareholders.

During the second quarter of 2026, the Company repurchased nearly 1.2 million shares of its common stock for a total cost of $31.5 million through its May 2026 share repurchase program, which provided for a total authorization of up to $200 million. To date, the Company has repurchased a cumulative 2 million shares of its common stock under this most recent program, and approximately $142.5 million remains under the existing authorization. — Progyny, Inc. 8-K filing · View on SEC EDGAR →

What this means

Progyny's $31.5 million Q2 buyback represents an execution of capital-allocation policy amid 5.3% revenue growth and strong profitability expansion. The average price paid ($26.25 per share) reflects the company's share price trajectory in 2026. With $142.5 million remaining under the May 2026 authorization and an additional predecessor program that retired 10.8 million shares across 2025–2026, the company is demonstrating a sustained commitment to shareholder returns while maintaining substantial liquidity ($236.9 million in cash and securities) and no debt. The buyback reduces share count—offsetting dilution from equity compensation—while the company invests in platform expansion and handles operational growth.

Frequently asked questions

What was the average price Progyny paid per share in Q2 2026?: Progyny repurchased nearly 1.2 million shares for $31.5 million, implying an average price of approximately $26.25 per share. The filing does not disclose the specific price range or execution window.
How much repurchase authorization remains?: Approximately $142.5 million remains under the May 2026 authorization of $200 million. The company has repurchased 2 million shares cumulatively to date under that program.
Why did Progyny start a new buyback program in May 2026 when it had a predecessor program?: The May 2026 program represented a new authorization, while the predecessor November 2025 program had concluded. The filing states that across both programs, the company has repurchased an aggregate 10.8 million shares, allowing Progyny to continue shareholder returns under the new authorization.
Does Progyny have sufficient cash to continue buybacks?: Yes. As of June 30, 2026, Progyny had $236.9 million in cash and marketable securities, no debt, and an undrawn $200 million revolving credit facility. The company's trailing twelve-month operating cash flow was $201.2 million, providing substantial financial flexibility.
What was the execution mechanism for the Q2 2026 buyback?: The filing does not specify whether the repurchases were executed under Rule 10b-18, a 10b5-1 plan, or another mechanism. Only the share count and total dollar amount are disclosed.
How do these buybacks affect Progyny's reported earnings per share?: Buybacks reduce share count, which mechanically supports earnings per share. In Q2 2026, diluted weighted-average shares outstanding were 82.1 million, down from 89.6 million in Q2 2025, reflecting both buyback activity and the company's organic focus on profitability expansion.

execution healthcare-sector women's-health Q2-2026 capital-allocation share-count-reduction

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.